Want to see ARTV full AI Analyst Report?
Top Page
Artiva Biotherapeutics, Inc.
(NASDAQ:ARTV)
Select Model
Select Model
Rating:58Neutral
Price Target:
$12.00
▲(19.64% Upside)
Action:Reiterated
Date:08/07/26
The score is primarily held back by weak financial performance: ongoing large losses, zero recent revenue, and substantial cash burn that necessitates external financing. This is partially offset by strong technical strength (price above all key moving averages with positive MACD) and supportive corporate developments (Phase 3 alignment and clinical data), while valuation remains unattractive/unclear due to negative earnings and no stated dividend yield.
Positive Factors
Clinical efficacy and tolerability
Robust Phase 2a outcomes (71% ACR50, deep B-cell depletion, favorable tolerability) materially de-risk AlloNK’s mechanism across B-cell autoimmune indications. Durable clinical proof-of-concept improves probability of successful registrational trial and long-term commercial potential.
Negative Factors
High cash burn
Persistent, large operating and free cash outflows indicate the business consumes significant cash to advance trials. That structural burn-rate necessitates repeated financing, constrains strategic optionality, and remains a core fundamental risk over a multi-quarter horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy and tolerability
Robust Phase 2a outcomes (71% ACR50, deep B-cell depletion, favorable tolerability) materially de-risk AlloNK’s mechanism across B-cell autoimmune indications. Durable clinical proof-of-concept improves probability of successful registrational trial and long-term commercial potential.
Read all positive factors
Artiva Biotherapeutics, Inc. (ARTV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$490.74M
Dividend YieldN/A
Average Volume (3M)572.32K
Price to Earnings (P/E)―
Beta (1Y)2.27
Revenue GrowthN/A
EPS Growth-18.99%
CountryUS
Employees104
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.31
Shares Outstanding48,588,200
10 Day Avg. Volume428,090
30 Day Avg. Volume572,322
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$31.76Price Target Upside216.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.67
Revenue Forecast (FY)N/A
Artiva Biotherapeutics, Inc. Business Overview & Revenue Model
Company Description
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeu...
How the Company Makes Money
null...
Artiva Biotherapeutics, Inc. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 251.00K | 33.49M | 4.93M | 2.00M |
| Gross Profit | -666.00K | -2.60M | 251.00K | 33.49M | 4.93M | 2.00M |
| EBITDA | -87.47M | -81.27M | -56.06M | -25.36M | -57.18M | -71.58M |
| Net Income | -90.82M | -83.86M | -58.49M | -27.70M | -58.39M | -71.83M |
Balance Sheet | ||||||
| Total Assets | 368.63M | 130.94M | 209.58M | 105.11M | 133.05M | 169.93M |
| Cash, Cash Equivalents and Short-Term Investments | 349.39M | 108.01M | 185.43M | 76.97M | 102.53M | 160.92M |
| Total Debt | 9.85M | 10.94M | 14.35M | 16.91M | 19.45M | 1.74M |
| Total Liabilities | 21.13M | 20.97M | 22.94M | 267.13M | 273.75M | 258.78M |
| Stockholders Equity | 347.50M | 109.97M | 186.64M | -162.01M | -140.70M | -88.86M |
Cash Flow | ||||||
| Free Cash Flow | -98.10M | -79.34M | -55.67M | -50.69M | -57.13M | -17.03M |
| Operating Cash Flow | -96.18M | -76.75M | -55.03M | -47.43M | -50.83M | -15.30M |
| Investing Cash Flow | 80.53M | 63.41M | -120.46M | -25.98M | -6.30M | -1.72M |
| Financing Cash Flow | 282.89M | 9.00K | 162.23M | 24.39M | -1.26M | 152.75M |
Artiva Biotherapeutics, Inc. Technical Analysis
Positive
10.03
Price Trends
9.28
Positive
8.96
Positive
6.67
Positive
Market Momentum
0.53
Negative
61.27
Neutral
79.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Positive. The current price of 10.03 is below the 20-day moving average (MA) of 10.20, above the 50-day MA of 9.28, and above the 200-day MA of 6.67, indicating a bullish trend. The MACD of 0.53 indicates Negative momentum. The RSI at 61.27 is Neutral, neither overbought nor oversold. The STOCH value of 79.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARTV.
Artiva Biotherapeutics, Inc. Risk Analysis
Artiva Biotherapeutics, Inc. disclosed 91 risk factors in its most recent earnings report. Artiva Biotherapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Artiva Biotherapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $490.74M | -2.85 | -53.86% | ― | ― | -18.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $85.16M | -0.61 | -74.90% | ― | ― | 27.27% | |
44 Neutral | $64.40M | -0.57 | -59.06% | ― | ― | 49.00% | |
43 Neutral | $17.69M | -0.19 | -523.04% | ― | ― | 38.53% | |
41 Neutral | $26.82M | -8.79 | -92.03% | ― | -100.00% | -170.04% |
* Healthcare Sector Average
ARTV
Artiva Biotherapeutics, Inc.
11.27
8.71
340.23%
ACET
Adicet Bio
7.98
-1.56
-16.37%
ABVC
ABVC BioPharma
1.02
-1.93
-65.42%
JSPR
Jasper Therapeutics
0.71
-1.92
-73.04%
PLRX
Pliant Therapeutics
1.05
-0.65
-38.24%
Artiva Biotherapeutics, Inc. Corporate Events
Regulatory Filings and ComplianceShareholder Meetings
Artiva Biotherapeutics Sets Deadline for 2026 Meeting
Neutral
Jul 22, 2026
Artiva Biotherapeutics, Inc. has scheduled its 2026 annual meeting of stockholders for September 8, 2026, a date that falls more than 70 days after the one-year anniversary of its 2025 annual meeting. As a result of this timing, the company has se...
Business Operations and StrategyExecutive/Board Changes
Artiva Biotherapeutics Announces Major Executive Leadership Transitions
Neutral
May 19, 2026
On May 18, 2026, Artiva Biotherapeutics announced several leadership changes, including the resignation of board member Diego Miralles, M.D., who left the Board to assume the role of President and Head of Research and Development, reducing the Boa...
Private Placements and FinancingRegulatory Filings and Compliance
Artiva Biotherapeutics Announces $300 Million Equity Offering
Positive
May 8, 2026
On May 8, 2026, Artiva Biotherapeutics, Inc. entered into an underwriting agreement with a syndicate of investment banks to issue 23,871,526 shares of common stock at $11.52 per share. The company also agreed to sell pre-funded warrants to purchas...
Business Operations and StrategyFinancial Disclosures
Artiva Highlights AlloNK RA Data and Phase 3 Alignment
Positive
May 8, 2026
Artiva Biotherapeutics reported first-quarter 2026 results on May 8, 2026, alongside initial clinical data showing strong efficacy and favorable tolerability for its lead NK cell therapy AlloNK in refractory rheumatoid arthritis and other B-cell-d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.